STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person
   Vatera Healthcare Partners LLC
   C/O VATERA HOLDINGS LLC
   499 PARK AVENUE, 23RD FLOOR
   NEW YORK NY 10022

2. Issuer Name and Ticker or Trading Symbol
   MELINTA THERAPEUTICS, INC. [MLNT]

3. Date of Earliest Transaction (Month/Day/Year)
   05/29/2018

5. Relationship of Reporting Person(s) to Issuer
   X Director
   X 10% Owner

6. Individual or Joint/Group Filing (Check Applicable Line)
   Form filed by One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>05/29/2018</td>
<td>p(1)</td>
<td>A</td>
<td>$5</td>
<td>16,007,237</td>
<td>D(2)(3)</td>
<td>See Footnotes(4)(5)</td>
</tr>
<tr>
<td>Common Stock</td>
<td>05/29/2018</td>
<td>p(1)</td>
<td>A</td>
<td>$5</td>
<td>16,607,959</td>
<td>I(2)(3)</td>
<td>See Footnotes(4)(5)</td>
</tr>
<tr>
<td>Common Stock</td>
<td>05/29/2018</td>
<td>p(1)</td>
<td>A</td>
<td>$5</td>
<td>16,607,959</td>
<td>I(2)(3)</td>
<td>See Footnotes(4)(5)</td>
</tr>
</tbody>
</table>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 5)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
1. Name and Address of Reporting Person

**VATERA HOLDINGS LLC**

<table>
<thead>
<tr>
<th>(Last)</th>
<th>(First)</th>
<th>(Middle)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C/O VATERA HOLDINGS LLC
499 PARK AVENUE, 23RD FLOOR

<table>
<thead>
<tr>
<th>(Street)</th>
<th>(City)</th>
<th>(State)</th>
<th>(Zip)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEW YORK</td>
<td>NY</td>
<td>10022</td>
<td></td>
</tr>
</tbody>
</table>

1. Name and Address of Reporting Person

**Ferro Kevin**

<table>
<thead>
<tr>
<th>(Last)</th>
<th>(First)</th>
<th>(Middle)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C/O VATERA HOLDINGS LLC
499 PARK AVENUE, 23RD FLOOR

<table>
<thead>
<tr>
<th>(Street)</th>
<th>(City)</th>
<th>(State)</th>
<th>(Zip)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NEW YORK</td>
<td>NY</td>
<td>10022</td>
<td></td>
</tr>
</tbody>
</table>

**Explanation of Responses:**
1. See Exhibit 99.1.
2. See Exhibit 99.1.
5. See Exhibit 99.1.

**Remarks:**
Exhibit List: Exhibit 99.1 - Explanation of Responses Exhibit 99.2 - Joint Filer's Signatures

**VATERA HEALTHCARE PARTNERS LLC, By: Vatera Holdings LLC, its Manager,**
**By: /s/ Kevin Ferro, Title: Chief Executive Officer, Chief Investment Officer and Managing Member**

05/31/2018

**Signature of Reporting Person**

**Date**

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Explanation of Responses

(1) These shares were purchased from the underwriters pursuant to an underwritten public offering by the Issuer. The offering closed on May 29, 2018.

(2) Includes 7,500,000 shares of Common Stock purchased directly by Vatera Healthcare Partners LLC and 378,500 shares of Common Stock purchased directly by VHPM Holdings LLC.

(3) Represents shares of Common Stock held directly by Vatera Healthcare Partners LLC, a Reporting Person on this Form 4.

(4) Vatera Holdings LLC is the manager of Vatera Healthcare Partners LLC and VHPM Holdings LLC and Kevin Ferro serves as the Chief Executive Officer, Chief Investment Officer and Managing Member of Vatera Holdings LLC. Vatera Holdings LLC and Mr. Ferro are Reporting Persons on this Form 4. Pursuant to Rule 13d-3 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"), Vatera Holdings LLC and Mr. Ferro may be deemed to beneficially own the shares held directly by Vatera Healthcare Partners LLC and VHPM Holdings LLC. Each of Vatera Holdings LLC and Mr. Ferro disclaims beneficial ownership of any shares owned by Vatera Healthcare Partners LLC or VHPM Holdings, except to the extent of its or his pecuniary interest therein.

(5) Mr. Ferro serves on the Board of Directors of the Issuer (the "Board"), together with Cecilia Gonzalo, a managing director of Vatera Holdings LLC, and Thomas P. Koestler, Ph.D., an executive director of Vatera Holdings LLC. Solely for purposes of Section 16 of the Exchange Act, Vatera Healthcare Partners LLC, VHPM Holdings LLC and Vatera Holdings LLC may be deemed to be directors-by-deputization as a result of the service of such persons on the Board.
JOINT FILERS' SIGNATURES

VATERA HOLDINGS LLC

By: /s/ Kevin Ferro

Name: Kevin Ferro
Title: Chief Executive Officer, Chief Investment Officer and Managing Member

By: /s/ Kevin Ferro

Kevin Ferro